Ipamorelin 10mg

Ipamorelin is a selective growth hormone secretagogue designed to stimulate natural GH release. This 10mg formulation supports lean muscle development, recovery optimization, and metabolic efficiency. Ideal for those seeking targeted performance enhancement with a research-backed peptide. Each vial delivers pharmaceutical-grade purity for consistent results.

Peptide Type: Growth Hormone Secretagogue Active Ingredient: Ipamorelin Concentration: 10mg per vial Purity: Pharmaceutical-grade Mechanism: Selective GH stimulation Primary Benefits: Lean muscle support, recovery enhancement, metabolic optimization Recommended Use: Performance and body composition optimization Storage: Cool, dry conditions Shelf Life: 24 months from manufacture

Molecular Formula: C38H49N9O5 Molecular Weight: 711.85 g/mol Structure: Pentapeptide (5 amino acid chain) Amino Acid Sequence: Alanyl-D-2-methylalanyl-D-2-methyltryptophyl-lysyl-prolyl amide CAS Number: 170851-70-4 Classification: Synthetic growth hormone-releasing peptide (GHRP) analog Stability: Stable under standard storage conditions

Research References

The following peer-reviewed studies and publications are provided for informational and scientific reference purposes only. They do not constitute medical claims or endorsements of this product for any therapeutic use.

1. Ipamorelin: Discovery as the First Selective GH Secretagogue
   Raun K, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561. https://doi.org/10.1530/eje.0.1390552
   The foundational characterisation study establishing ipamorelin as the first highly selective GH secretagogue, demonstrating potent GH release with minimal effect on ACTH, cortisol, and prolactin in rat models — distinguishing it from GHRP-6 and GHRP-2 and establishing its selectivity profile for GH-axis research.
2. Ipamorelin and GHS-R1a Receptor Pharmacology
   Howard AD, et al. (1996). A receptor in pituitary and hypothalamus that functions in growth hormone release. Science, 273(5277), 974–977. https://doi.org/10.1126/science.273.5277.974
   Reports the cloning and characterisation of GHS-R1a — the primary molecular target of ipamorelin — establishing the receptor biology and signal transduction pathways through which ipamorelin stimulates pulsatile GH secretion from anterior pituitary somatotrophs.
3. Ipamorelin and Postoperative Gut Motility
   Poitras P, et al. (2005). Ipamorelin, a ghrelin mimetic, stimulates gastrointestinal motility in postoperative ileus in rats. Neurogastroenterology & Motility, 17(6), 892–901. https://doi.org/10.1111/j.1365-2982.2005.00699.x
   Demonstrates ipamorelin’s ability to stimulate gastrointestinal motility and accelerate recovery from postoperative ileus in rat models via GHS-R1a activation in the enteric nervous system, expanding its research scope beyond the GH axis into gastrointestinal biology.
4. Ipamorelin and Bone Density in Preclinical Models
   Svensson J, et al. (2000). Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. (See also: Johansen PB, et al. (1999). Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research, 9(2), 106–113.) https://doi.org/10.1054/ghir.1999.9998
   Demonstrates ipamorelin-induced longitudinal bone growth and increased bone mineral density in rat models via GH/IGF-1 axis stimulation, providing key preclinical data for researchers investigating GHS-R1a agonism in skeletal biology and bone metabolism.
5. Ipamorelin + CJC-1295 Synergy: Combined GH Secretagogue Research
   Teichman SL, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
   Provides the pharmacodynamic basis for combining GHRH analogues with GHS-R1a agonists such as ipamorelin, demonstrating synergistic amplification of GH pulse amplitude — the key reference for researchers designing combination CJC-1295 + ipamorelin protocols.

All references are cited for scientific context only. This product is supplied strictly for in vitro laboratory research. It is not approved for human or veterinary use.

Storage Before Reconstitution (Lyophilized Powder): Temperature: 2–8°C (refrigerated) or 15–25°C (room temperature) Environment: Dark, dry location away from direct sunlight Humidity: Below 60% relative humidity Container: Original sealed vial with desiccant Shelf Life: 24 months from manufacture date Handling: Minimize exposure to air and moisture Storage After Reconstitution (Liquid Solution): Temperature: 2–8°C (refrigerated) Duration: Use within 14–30 days depending on reconstitution medium Container: Sterile vial with bacteriostatic water or saline Stability: Reduced once reconstituted; degradation accelerates at room temperature Handling: Store upright, avoid repeated freeze-thaw cycles Discard: Any solution showing discoloration, cloudiness, or particulates